Clinical Value Considerations for Gene Therapy in Spinal Muscular Atrophy
Join us as we explore recent data updates for gene therapy in spinal muscular atrophy (SMA) and gain a deeper understanding of its clinical value.
In this webinar, experts will share and discuss current data pertaining to motor milestone achievement in presymptomatic patients with 3 copies of survival motor neuron 2 (SMN2). The importance of biodistribution and bulbar function will also be discussed.
- Brian Howell, PharmD
Novartis Gene Therapies Regional Medical Director
- Nicole LaMarca, DNP
Novartis Gene Therapies Global Medical Director, Data Exploration and Generation Lead
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
For individuals from the media/press who are interested in attending, please email email@example.com.